GRTXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (10 5月 2024 @ 05:00):

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer...

Stats
本日の出来高	322 228
平均出来高	2.08M
時価総額	9.63M
EPS	$0 ( 2024-05-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.130
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Schneid Yair	Buy	99 371	Common Stock
2024-04-19	Schneid Yair	Buy	215	Common Stock
2024-04-19	Schneid Yair	Buy	314	Common Stock
2024-04-19	Schneid Yair	Buy	100	Common Stock
2024-04-18	Schneid Yair	Buy	74 202	Common Stock

INSIDER POWER
99.83
Last 95 transactions
Buy: 7 344 028 \| Sell: 846 527

ボリューム相関

長: 0.08 (neutral)

短: -0.06 (neutral)

Signal:(38.275) Neutral

Galera Therapeutics Inc 相関

10 最も正の相関
LIAN	0.848
IMAB	0.843
MEUSW	0.842
PXLW	0.841
ADXN	0.839
LEGO	0.833
FORA	0.828
VYGR	0.814

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Galera Therapeutics Inc 相関 - 通貨/商品

0.00
( neutral )

-0.43
( neutral )

Galera Therapeutics Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$-259 000 (0.00 %)
EPS:	$-1.330

FY	2023
収益:	$0
総利益:	$-259 000 (0.00 %)
EPS:	$-1.330

FY	2022
収益:	$0
総利益:	$-114 000 (0.00 %)
EPS:	$-2.30

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-3.06

Financial Reports:

No articles found.

Galera Therapeutics Inc

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.